ABOUT US
Endosure, Inc. was created based upon a new approach to support physicians in the diagnosis of endometriosis. The EndoSure Test* is uniquely poised to change the diagnostic paradigm for endometriosis and facilitate the pathway to early diagnosis, which in turn can enhance timely treatment options. Our first of its kind non-invasive, 30-minute endometriosis clinical decision support tool offers the promise to improve the lives and livelihoods of the hundreds of millions of women that suffer from this disease yearly. Supporting the Company’s compelling technology is a world class senior team with transformational skills that will enhance commercialization.
TEAM
CARLOS BABINI
Chief Executive Officer
Carlos BABINI is a recognized leader in many sectors of the medical device space with reputation for building world class organizations. Mr. BABINI brings more than 25 years of successful commercialization and leadership experience to ENDOSURE, with distinguished performance in public and private companies. Previously, he has served as CEO of USGI Medical, Inc. a medical company specializing in non-invasive endoluminal procedures, as well as Vice President of AirSeal System Commercialization for Conmed Corporation, and Chief Commercialization Officer at SurgiQuest, Inc., a medical company offering innovative surgical devices for laparoscopic and robotic surgery, prior to its acquisition by Conmed. Carlos also served as President, International for Curon, Inc. and Chief Sales and Marketing Officer of the medical segment of Vision Sciences Inc., which was acquired by Cogentix Medical and subsequently by Laborie Medical Technologies.
He has also held various executive positions at United States Surgical Corporation where he was instrumental in launching minimally invasive surgery globally and training thousands of surgeons worldwide prior to its acquisition by Tyco International, LTD. and subsequently by Medtronic.
CHERYL KALLEM
Chief Financial Officer
Cheryl KALLEM has had a successful career in all aspects of financial and operations management. After beginning her career in public accounting, Cheryl has held roles of increasing responsibility at several financial services companies, culminating as a Senior Managing Director and the Chief Financial and Operations Officer at First Manhattan Company, an investment advisory firm located in Manhattan. In recent years, Cheryl has joined Golden Seeds, an Angel investment group, as a Managing Director.
Ms. KALLEM is an active Angel investor and has served as a mentor to senior management of many early-stage companies.
Additionally, she is the Vice Chair and a Board Member of the Northern Manhattan Improvement Corporation, a settlement house based in Washington Heights and a board member and treasurer of the board of her cooperative apartment building. Cheryl also volunteers at and is an ardent supporter of the ASPCA.
MARK NOAR
Chief of Strategic Development and Compliance
Dr. Mark NOAR serves the company as the Chief of Strategic Development and Compliance. He brings to ENDOSURE more than 25 years of experience in hardware and software development and integration in the medical device industry as well as clinical and research-based practice in gastroenterology and surgery.
He is the inventor of the TRICORDER-3L technology and a host of other inventions and innovations in the fields of interventional endoscopy, medical education, and simulation. He is responsible for developing the ENDOSURE TEST* including the Ai based software that supports non-invasive diagnosis of Endometriosis. He has directed multiple clinical research projects, in the fields of obesity, reflux, and gastrointestinal motility, including elevating the importance of Electrogastrography as a successful diagnostic tool.
Dr. NOAR has authored numerous publications and produced several award-winning video educational materials and simulators in endoscopy and laparoscopic surgery. He also serves as an advisor to the pharmaceutical, medical device and financial industries. Mark has a history of creating breakthrough technologies and has been credited with saving lives and limiting patient complications worldwide.
About Us
EndoSure offers the only non-invasive, 30-minute test to support the diagnosis of endometriosis that not only fills the gap, but addresses the vacuum in this area of women’s health care.*
© July 2024 ENDOSURE, Inc. All rights reserved
1. Approximately 15-20 minutes of patient preparation time may be required prior to performing the test.
2. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
3. i. Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024 May 13;13(10):2866. doi: 10.3390/jcm13102866. PMID: 38792407; PMCID: PMC11122642.
4. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Viganò, P. Endometriosis. Nat. Rev. Dis. Primers. 2018:4-9.
5. 1. Noar M, Mathias J, Kolatkar A. Validation of New GIMA Biomarker Signature of Endometriosis - Interim Data: Research Article. TechRxiv. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
6. 1. Kitsantas P, Benson KN, Al-Farauki S, Knecht MK, Hennekens CH, et al. (2024) Emerging Diagnostic Tools for the Early Diagnosis of Endometriosis. J Reprod Med Gynecol Obstet 9: 171.
DISCLAIMER: THE ENDOSURE TEST IS A CLINICAL DECISION SUPPORT TOOL INTENDED TO INFORM AND ENHANCE A HEALTHCARE PROVIDER'S DECISION-MAKING PROCESS, WHICH MUST BE INDIVIDUALIZED FOR EACH PATIENT'S CIRCUMSTANCES AND TAKE INTO ACCOUNT THE FULL SCOPE OF MEDICAL DATA AND INFORMATION AVAILABLE TO THE PROVIDER. THE ENDOSURE TEST IS NOT INTENDED TO SUBSTITUTE, REPLACE, OVERRULE, OR DIRECT A HEALTHCARE PROVIDER’S JUDGMENT.
* US CUSTOMERS: Endosure is currently available for research use only and not clinical use.